DiagnoCure's Update Presentation during the Annual and Special Meeting of Shareholders
April 29 2013 - 6:30AM
OTC Markets
DiagnoCure's Update Presentation during the Annual and Special
Meeting of Shareholders
#ReleaseContent TABLE
{
BORDER-COLLAPSE: collapse
}
TR.cnwUnderlinedCell TD
{
BORDER-BOTTOM: #000000 1px solid
}
TR.cnwDoubleUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px double
}
TR.cnwBoldUnderlinedCell TD
{
BORDER-BOTTOM: #000000 3px solid
}
TD.cnwUnderlinedCell
{
BORDER-BOTTOM: #000000 1px solid
}
TD.cnwDoubleUnderlinedCell
{
BORDER-BOTTOM: #000000 3px double
}
TD.cnwBoldUnderlinedCell
{
BORDER-BOTTOM: #000000 3px solid
}
#ReleaseContent TABLE.cnwBorderedTable TD
{
BORDER-RIGHT: black 1px solid;
PADDING-RIGHT: 2px;
BORDER-TOP: black 1px solid;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
BORDER-LEFT: black 1px solid;
PADDING-TOP: 2px;
BORDER-BOTTOM: black 1px solid;
BORDER-COLLAPSE: collapse
}
#ReleaseContent TABLE TD
{
PADDING-RIGHT: 2px;
PADDING-LEFT: 2px;
PADDING-BOTTOM: 2px;
PADDING-TOP: 2px
}
DiagnoCure's Update Presentation during the Annual and Special
Meeting of Shareholders
PR Newswire
QUEBEC CITY, April 29, 2013
QUEBEC CITY, April 29, 2013 /PRNewswire/ - DiagnoCure Inc.
(TSX: CUR)
(OTCQX: DGCRF) reminds shareholders to attend its Annual and
Special
Meeting of Shareholders to be held today, April 29th, at 3pm EDT, at the offices of McCarthy Tetrault,
1000 de la
Gauchetière Street West, Suite 2500, Montreal, Quebec, H3B 0A2.
At the completion of the formal business portion of the meeting,
Dr.
Yves Fradet, President and Chief
Medical Officer will make a
presentation during which he will touch upon the following
topics:
An update on the Corporation's current status of the GCC and
PCA3
products;
A review of the Corporation's business model evolution;
Initiation of a search for a full-time CEO to achieve maximum
leverage
from DiagnoCure's product development platform.
The presentation will be available on DiagnoCure's website at
www.diagnocure.com through a link on the Investors page;
presentations, available from 3pm
for those unable to attend the meeting.
About DiagnoCure
DiagnoCure (TSX: CUR; OTCQX: DGCRF) is a life sciences corporation
that
develops and commercializes high-value cancer diagnostic tests
that
increase clinician and patient confidence in making critical
treatment
decisions. In 2008, the Corporation launched a colorectal
cancer
staging test through its U.S. CLIA laboratory.
PrevistageTM GCC is currently available for licensing.
The Corporation has granted a
worldwide exclusive license to Gen-Probe, now a wholly-owned
subsidiary
of Hologic Inc. operating as Hologic Gen-Probe, for the development
and
commercialization of a prostate cancer test using PCA3,
DiagnoCure's
proprietary molecular biomarker. Hologic Gen-Probe's
PROGENSA® PCA3 test is commercialized in Europe under CE mark and is approved for
commercialization in Canada and
the United States. For more
information, please visit www.diagnocure.com.
Forward?looking statements
This release may contain forward?looking statements that involve
known
and unknown risks, uncertainties and assumptions that may cause
actual
results to differ materially from those expected.
Forward-looking
statements can be identified by the use of the conditional or
forward-looking terminology such as "anticipates", "assumes",
"believes", "estimates", "expects", "intend", "may", "plans",
"projects", "should", "will", or the negative thereof or other
variations thereon. Forward-looking statements also include any
other
statements that do not refer to historical facts. All such
forward-looking statements are made pursuant to the
"safe-harbour"
provisions of applicable Canadian securities laws. By their
very
nature, forward?looking statements are based on expectations
and
hypotheses and also involve risks and uncertainties, known and
unknown,
many of which are beyond DiagnoCure's control. Forward-looking
statements are presented for the purpose of assisting investors
and
others in understanding certain key elements of the
Corporation's
current objectives, strategic priorities, expectations and plans,
and
in obtaining a better understanding of the Corporation's business
and
anticipated operating environment. Readers are cautioned that
such
information may not be appropriate for other purposes and that
they
should not place undue reliance on these forward?looking
statements.
For instance, any forward-looking statements regarding the outcome
of
research and development projects, clinical studies and future
revenues, including those related to PROGENSA® PCA3, are
based on management expectations and such outcome may vary
materially depending on global political and economic
conditions,
dependence on collaboration partners, uncertainty of healthcare
reimbursement, and marketing and distribution challenges. In
addition,
the reader is referred to the applicable general risks and
uncertainties described in DiagnoCure's most recent Annual
Information
Form under the heading "Risk Factors". DiagnoCure undertakes no
obligation to publicly update or revise any forward?looking
statements
contained herein unless required by the applicable securities laws
and
regulations.
SOURCE DiagnoCure inc.
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Diagnocure (CE) (USOTC:DGCRF)
Historical Stock Chart
From Jul 2023 to Jul 2024